IBI Ag Nanobody Bioinsecticides

IBI-Ag Ltd develops next-generation bioinsecticides using proprietary proteins and AI-driven design, aiming for precision, safety and sustainability in crop protection. A news item on its site describes it as an Israeli ag-biotech firm that set up a North American headquarters in Indiana in September 2026.

Its first-generation products are nanobody-based, single-domain antibody bioinsecticides engineered to target specific insect species. A second-generation AI de novo design platform creates new bioinsecticide proteins, with a lab-in-the-loop process feeding experimental data back into computational design. The company claims it can move from target to candidate in 4 months.

• Nanobody products: first-generation single-domain antibody bioinsecticides.
• AI de novo design: second-generation platform that designs new bioinsecticide proteins.
• Species precision: proteins engineered for specific insect targets.
• Lab-in-the-loop: experimental testing feeds data back into computational design.
• Bottom-up approach: a new mode of action is chosen first and the product built around it.

Crop-protection distributors in Vietnam could track nanobody bioinsecticides as a future option for vegetable and fruit pests. Research institutes could explore partnerships on region-specific pests. Export growers facing residue limits could evaluate such products once registered.

Proteins are engineered to target specific insect species, supporting precision pest control. Naturally derived proteins leave no synthetic chemical residues. The AI platform shortens the path from target to candidate to about 4 months, according to the company. A new mode of action can help where resistance limits current products.

Insecticide resistance and tighter chemical regulation are driving investment in biological and protein-based pest control. Agrochemical majors are backing biologicals startups through venture arms. Southeast Asian vegetable and rice growers face heavy insecticide use and growing residue scrutiny.

Israeli ag-biotech company. Completed a $10 million Series A led by Corteva in November 2025. Announced an AI de novo protein design platform in March 2026. Recognized as a Hello Tomorrow Deep Tech Pioneer in February 2026. North American headquarters in Indiana announced in September 2026.